ISPAD Interview with Wojciech Fendler
1)    If you were to sum up the most important characteristics of your work in one sentence, what would they be?

I focus on the applications of biostatistics and bioinformatics in molecular medicine – an interdisciplinary skillset that I am training my team in.
 
2)    Who, or what, inspired you to enter this field of work?

After finishing my medical studies I got involved in a research project headed by Prof. Wojciech Mlynarski – himself an ISPAD Young Investigator Award recipient. This initiative resulted in the assembly of one of the largest groups of children with monogenic diabetes. Working as part of the group between 2008 and 2013 was an amazing adventure. Prof. Mlynarski drew my interests on neonatal and MODY diabetes with a focus on biostatistics and epidemiology. As the projects progressed I turned to the field of biomarkers of monogenic diabetes, particularly microRNAs.
     
3)    What role did / does ISPAD play in your work?

The ISPAD Science School in 2008 in Estes Park, USA organized by the amazing team of the Barbara Davis Center in Denver taught me the basics of good research practice in diabetes and set me on the right track. Continuous support from ISPAD and ample opportunities for scientific collaboration are an amazing way of promoting young researchers and to promote our findings. The visibility of our results granted through ISPAD’s Annual Conferences and the Pediatric Diabetes journal allowed us to easily forge international collaborations and effectively reach patients in need of genetic counseling from countries without such programs.
 
4)    What, do you think, should be the next breakthrough in your field of diabetes research and/or care?

After a widespread integration of the closed loop system into clinical practice, the identification of patients with strong predisposition to diabetic complications will probably grow in importance. The decreasing costs of genetic studies and improved capabilities for harnessing that information makes the widespread use of high throughput genetic screening in every child with diabetes more and more feasible. This will identify the ~5% of individuals with monogenic diabetes and, through the application of various genetic risk scores, stratify the patients’ risk of diabetes complications and identify the best therapeutic approach.
 
5)    What are your plans for the future?

To continue our work on the regulatory networks associated with transcription factor defects responsible for monogenic diabetes. My ongoing project focuses on the modulatory role of microRNAs and other non-coding RNAs in the pathogenesis of monogenic diabetes and its clinical course. Hopefully, I will have something exciting to show at ISPAD 2017.

Contact Us

ISPAD Executive Office
c/o K.I.T. Group GmbH
Association & Conference Management
Kurfürstendamm 71
10709 Berlin, Germany










Join ISPAD

Click the link below to join the Society!


Join Today!










Phone: +49 (0)30 24603-210
Fax: +49 (0)30 24603-200
Email: secretariat@ispad.or
g










Privacy Policy
Terms of Service
Legal Notice    

Disclaimer



































 © 2017 International Society for Pediatric and Adolescent Diabetes (ISPAD)






Association Management Software Powered by YourMembership  ::  Legal